Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

2078 - Survival of patients with synchronous and metachronous breast cancer and meningioma


08 Oct 2016


CNS tumours


Catarina Ribeiro


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


C.G. Ribeiro1, L. Mascarenhas2, J.P. Lavrador3, A. Peralta4, M. Valente5

Author affiliations

  • 1 Dept. Of Oncology, Centro Hospitalar Lisboa Central-CHLC-Hospital São Jose, 1169-050 - Lisboa/PT
  • 2 Pathology, Centro Hospitalar Lisboa Central-CHLC-Hospital São Jose, 1169-050 - Lisboa/PT
  • 3 Neurosurgery, Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), 1169-050 - Lisboa/PT
  • 4 Public Health, Public Health, 1000 - Lisboa/PT
  • 5 Pediatrics, John Radcliffe Hospital University of Oxford, OX3 9DU - Oxford/GB


Abstract 2078


The prognostic relevance of the association between Breast Cancer (BC) and Meningioma (M) is still unknown. Therefore, our aim was to evaluate the survival impact of tumor exposure sequence - synchronous or metachronous - in patients with these tumors.


Patients were divided in three groups according to the exposure

variable – sequence of tumors: M before BC (M → BC), synchronous BC and M (BC + M) and BC before M (BC → M). Only patients exclusively with both these tumors were included. The SEER database was used. Demographic variables, meningioma variables (site, grade and treatment) and breast cancer variables (grade, stage, hormonal receptor status and treatment) were collected and the primary outcome was oncological survival.


A total of 1715 patients were followed for a median follow-up of 84 months. The BC + M group had the shortest survival (median of 32 months) and BC → M the longest (median of 110 months). The unadjusted analysis revealed BC + M group as statistically related to the shortest survival (HR 3.13, 95%[CI] [1.62-6.04]). The adjusted analysis confirmed that the BC + M group as the one with worst prognosis (HR 3.11, 95%[CI] [1.58-6.19]), with no statistical difference between the metachronous tumors . Increasing age (HR:1.13, 95%CI: 1.11-1.15, p  0.05) but have no influence on metachronous tumors survival (p 


Synchronous BC and M were associated with lower survival, when compared with metachronous tumors. Increasing age had a negative influence on patients' survival. Grade III meningioma and hormonal receptor status only influenced synchronous tumors oncological survival.

Clinical trial identification

Legal entity responsible for the study

Clinical Scholars Research Training Program, Harvard Medical School Portugal




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings